Structure Therapeutics (GPCR) stock price is $22.88, up 3.95% on the day, as of Oct 20, 2026. It has a market cap of $5.02Bn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap5.02 Bn
P/E-23.35
Div. Yield0.00
Add ratio to table…
About
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company focused on discovering and developing oral small molecule therapeutics for chronic diseases with unmet medical need. The company uses a structure based drug discovery platform that combines expertise in GPCR structural biology with computational chemistry methods to design molecules that modulate protein coupled receptors. Its lead candidate aleniglipron also known as GSBR 1290 is an oral small…
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company focused on discovering and developing oral small molecule therapeutics for chronic diseases with unmet medical need. The company uses a structure based drug discovery platform that combines expertise in GPCR structural biology with computational chemistry methods to design molecules that modulate protein coupled receptors. Its lead candidate aleniglipron also known as GSBR 1290 is an oral small molecule selective GLP1R agonist currently evaluated in multiple Phase 2 studies for obesity overweight and related conditions. In addition the company advances two oral small molecule amylin receptor agonists ACCG 2671 and ACCG 3535 which are in Phase 1 and preclinical stages respectively. The pipeline also includes early stage programs targeting GIP receptors and glucagon receptors for potential combination therapy. Further programs investigate APJ receptor agonism for pulmonary arterial hypertension and LPA1 receptor antagonism for idiopathic pulmonary fibrosis. The company highlights a current manufacturing capacity of six thousand tons per year of aleniglipron which it states is sufficient to supply treatment to more than one hundred twenty million patients annually. All research development and intellectual property are held through wholly owned subsidiaries such as Gasherbrum Bio Aconcagua Bio Gimigela Bio Annapurna Bio and Lhotse Bio.
Structure Therapeutics Inc generates revenue primarily through upfront payments milestone payments and royalties from strategic collaborations and licensing agreements. The company has a collaboration agreement with Schrödinger that provides computational chemistry support and requires monthly active program payments in the low six digits. Under this agreement Schrödinger is entitled to milestone payments up to an aggregate of eighty nine million dollars for the first Aconcagua collaboration product to achieve a particular milestone event and tiered royalties in the low single digit range on worldwide net sales of collaboration products. In December 2025 the company signed a license agreement with Genentech and Roche granting a non exclusive royalty bearing license on certain patents covering a class of oral GLP1R agonists distinct from aleneglipron. Under this agreement Genentech paid an upfront non refundable payment of one hundred million dollars within thirty days of execution and agreed to pay royalties at a low single digit rate on net sales of the licensed products. Additional revenue may arise from future milestone payments under the Schrödinger collaboration as development programs advance and from potential royalties if licensed product candidates reach commercialization. The company does not yet market any product so its current revenue consists of these collaboration and licensing proceeds.
Structure Therapeutics Inc positions itself as an innovator in the oral small molecule arena for GPCR targets where peptide and biologic therapies currently dominate the market. Competitors developing oral small molecule GLP1R agonists include Pfizer Eli Lilly Qilu Regor Therapeutics AstraZeneca Eccogene Terns Pharmaceuticals Jiangsu Hengrui Medicine Huadong Sciwind Biosciences Ascletis Gilead Kallyope MindRank vTv Therapeutics Carmot Therapeutics Kailera Therapeutics and Merck. Approved peptide GLP1R agonists are sold by Novo Nordisk Eli Lilly AstraZeneca Sanofi and Kailera Therapeutics. In the amylin space no oral small molecule therapy has been approved and preclinical activity is reported from companies such as Eli Lilly Eccogene Nxera Iktos Cube Biotech Alveus Therapeutics and Ambrosia Biosciences. The company differentiates itself through its proprietary structure based drug discovery platform that integrates three dimensional protein structure visualization with advanced physics based computational methods. This approach enables the design of biased agonists that preferentially activate G protein pathways while avoiding beta arrestin signaling which may improve efficacy and reduce dosing requirements. Manufacturing scalability is another advantage with the stated capacity to produce six thousand tons of aleneglipron per year enough to treat over one hundred twenty million patients annually. The company also maintains a growing patent portfolio with over four hundred eighty patents and patent applications worldwide as of December 2025 providing protection for its product candidates and associated technologies. These factors collectively aim to give Structure Therapeutics Inc a competitive edge in bringing oral small molecule therapies to patients with chronic metabolic cardiovascular and pulmonary diseases.
Structure Therapeutics Inc serves patients who suffer from obesity overweight type two diabetes mellitus and related cardiometabolic conditions such as heart failure sleep apnea chronic kidney disease osteoarthritis metabolic dysfunction associated steatotic liver disease and potentially neurodegenerative disorders. The company’s therapeutic approach aims to provide accessible oral alternatives to injectable peptide therapies thereby addressing issues of patient convenience storage and cost. In addition to patients the company works with collaboration partners that provide essential capabilities and financial support. Key partners include Schrödinger which supplies computational chemistry and modeling expertise and Genentech and Roche which provide licensing rights and upfront financial consideration. These partners are important customers that help fund research development and may participate in future commercialization efforts. The company also anticipates that healthcare providers payors and health systems will become customers once its product candidates receive regulatory approval and reach the market.
Sector:HealthcareSector rationaleStructure Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule therapeutics for chronic diseases, such as obesity and type 2 diabetes. Its revenue is derived from licensing agreements and milestone payments from other pharmaceutical companies (Genentech, Roche) for its drug candidates, which is a standard revenue model for the Biotechnology and Pharmaceuticals industries within the Healthcare sector.Industries:PharmaceuticalsPharmaceuticalsPrimaryStructure Therapeutics is a biopharmaceutical company focused on discovering and developing oral small molecule therapeutics, such as aleniglipron (a GLP1R agonist) and amylin receptor agonists. Because its pipeline consists of small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification.BiotechnologyBiotechnologySecondaryThe company operates as a clinical-stage developer that generates revenue through upfront payments, milestone payments, and royalties from strategic collaborations, such as its agreements with Schrödinger and Genentech/Roche.Classified using BQ-MICSCIK: 0001888886
Bull & bear
Investment Thesis
▲ Bull case
Structure Therapeutics (GPCR) possesses a compelling pipeline advantage with aleniglipron, a once-daily oral GLP-1 receptor agonist that demonstrated robust weight loss efficacy of up to 15.3% at 240mg dose in Phase 2 trials at 36 weeks, with continued weight loss observed in open-label extension data showing 15.3% placebo-adjusted mean weight loss at 120mg dose after a median 20-week follow-up, positioning the drug competitively against injectable alternatives while offering superior patient convenience and adherence potential critical for chronic obesity management.
The company's strategic focus on combination therapy represents a significant undervalued catalyst, as preclinical and early clinical data indicate aleniglipron can be effectively paired with its amylin-gut hormone targeting drug to achieve synergistic effects greater than monotherapy, with additional combinability potential with PCSK9 inhibitors for cardiovascular risk reduction, allowing Structure to address comorbid conditions like fatty liver disease and chronic kidney disease that segment the obesity market and create premium pricing opportunities beyond simple weight loss indications.
Alegenlipron's favorable tolerability profile, evidenced by only 10.4% discontinuation rate in Phase 2 trials and no drug-related liver injuries across studies—differentiating it from failed oral obesity candidates—combined with a low 2.5mg starting dose enabling dose titration to mitigate gastrointestinal side effects, supports successful Phase 3 trial execution planned for Q3 2026 and enhances real-world adherence, particularly among primary care physicians who prefer oral therapies for the 100 million U.S. obesity patients currently underserved by injectable-only options.
Structural manufacturing advantages as a small-molecule drug enable scalable, low-cost production capable of supplying the entire U.S. market, contrasting with complex biologics used in injectable GLP-1s, which positions Structure to capitalize on impending Medicare coverage for obesity drugs later this year and potential price reductions by Novo Nordisk and Eli Lilly, as CEO Ray Stevens explicitly states the company is 'okay with cost dropping' because success hinges on volume penetration of the vast unmet need rather than premium pricing, aligning incentives with broad market adoption.
The upcoming Phase 3 trial readout in late 2027 or early 2028 serves as a near-term inflection point that the market may be underestimating, given the drug's demonstrated durability of effect without weight loss plateau in extension studies and its oral administration advantage in a market where only 5 million of 100 million needing treatment currently receive therapy, creating a scenario where even modest market share capture could drive substantial revenue growth given the multi-billion dollar obesity therapeutics opportunity.
Structure Therapeutics (GPCR) possesses a compelling pipeline advantage with aleniglipron, a once-daily oral GLP-1 receptor agonist that demonstrated robust weight loss efficacy of up to 15.3% at 240mg dose in Phase 2 trials at 36 weeks, with continued weight loss observed in open-label extension data showing 15.3% placebo-adjusted mean weight loss at 120mg dose after a median 20-week follow-up, positioning the drug competitively against injectable alternatives while offering superior patient convenience and adherence potential critical for chronic obesity management.
The company's strategic focus on combination therapy represents a significant undervalued catalyst, as preclinical and early clinical data indicate aleniglipron can be effectively paired with its amylin-gut hormone targeting drug to achieve synergistic effects greater than monotherapy, with additional combinability potential with PCSK9 inhibitors for cardiovascular risk reduction, allowing Structure to address comorbid conditions like fatty liver disease and chronic kidney disease that segment the obesity market and create premium pricing opportunities beyond simple weight loss indications.
Alegenlipron's favorable tolerability profile, evidenced by only 10.4% discontinuation rate in Phase 2 trials and no drug-related liver injuries across studies—differentiating it from failed oral obesity candidates—combined with a low 2.5mg starting dose enabling dose titration to mitigate gastrointestinal side effects, supports successful Phase 3 trial execution planned for Q3 2026 and enhances real-world adherence, particularly among primary care physicians who prefer oral therapies for the 100 million U.S. obesity patients currently underserved by injectable-only options.
Structural manufacturing advantages as a small-molecule drug enable scalable, low-cost production capable of supplying the entire U.S. market, contrasting with complex biologics used in injectable GLP-1s, which positions Structure to capitalize on impending Medicare coverage for obesity drugs later this year and potential price reductions by Novo Nordisk and Eli Lilly, as CEO Ray Stevens explicitly states the company is 'okay with cost dropping' because success hinges on volume penetration of the vast unmet need rather than premium pricing, aligning incentives with broad market adoption.
The upcoming Phase 3 trial readout in late 2027 or early 2028 serves as a near-term inflection point that the market may be underestimating, given the drug's demonstrated durability of effect without weight loss plateau in extension studies and its oral administration advantage in a market where only 5 million of 100 million needing treatment currently receive therapy, creating a scenario where even modest market share capture could drive substantial revenue growth given the multi-billion dollar obesity therapeutics opportunity.
Structure Therapeutics (GPCR) faces significant clinical execution risk as its Phase 3 trial for aleniglipron is not scheduled to begin until Q3 2026, creating an approximately two-year window where competitors like Novo Nordisk's oral semaglutide and Eli Lilly's orforglipron could establish entrenched market position, brand loyalty, and physician prescribing patterns that may be difficult to displace despite Structure's claimed advantages in tolerability and combinability.
The obesity drug market is evolving toward combination therapies as the next competitive battleground, yet Structure's amylin-gut hormone combination data remains preclinical or early-stage with no disclosed timeline for clinical testing, leaving the company vulnerable to being perceived as a monotherapy player in a market where winners like Novo Nordisk and Eli Lilly are already advancing their own combination pipelines, potentially diminishing the long-term differentiation value of aleniglipron as a standalone agent.
Although aleneglipron showed no liver injury signals, gastrointestinal side effects remain prevalent—including nausea, diarrhea, vomiting, and constipation—with serious adverse events occurring in 12% of patients at the 120mg dose (four out of a limited sample), and the company's reliance on dose interruption and reduction strategies to manage tolerability may not translate to real-world settings where primary care physicians lack specialized support, potentially undermining the touted adherence advantage over injectables that offer more predictable pharmacokinetics.
Structural manufacturing cost advantages as a small-molecule drug may be offset by intense pricing pressure in the obesity space, as Medicare coverage later this year and aggressive cash price cuts by Novo Nordisk and Eli Lilly could drive down reimbursement rates across the class, threatening Structure's profitability even if it achieves market share, particularly given its lack of scale, diversified revenue streams, or established commercial infrastructure compared to incumbent pharmaceutical giants.
The market may be overestimating the addressable population for oral obesity drugs, as primary care physician preference for pills does not guarantee uptake given persistent side effect burdens, lack of long-term safety data beyond 44 weeks, and potential formulary restrictions favoring established injectables with proven cardiovascular outcomes data, meaning Structure could capture far less than the anticipated share of the 100 million needing treatment, leaving its valuation dependent on successful Phase 3 outcomes that remain years away and subject to clinical trial failure risks inherent in mid-stage biotech programs.
Structure Therapeutics (GPCR) faces significant clinical execution risk as its Phase 3 trial for aleniglipron is not scheduled to begin until Q3 2026, creating an approximately two-year window where competitors like Novo Nordisk's oral semaglutide and Eli Lilly's orforglipron could establish entrenched market position, brand loyalty, and physician prescribing patterns that may be difficult to displace despite Structure's claimed advantages in tolerability and combinability.
The obesity drug market is evolving toward combination therapies as the next competitive battleground, yet Structure's amylin-gut hormone combination data remains preclinical or early-stage with no disclosed timeline for clinical testing, leaving the company vulnerable to being perceived as a monotherapy player in a market where winners like Novo Nordisk and Eli Lilly are already advancing their own combination pipelines, potentially diminishing the long-term differentiation value of aleniglipron as a standalone agent.
Although aleneglipron showed no liver injury signals, gastrointestinal side effects remain prevalent—including nausea, diarrhea, vomiting, and constipation—with serious adverse events occurring in 12% of patients at the 120mg dose (four out of a limited sample), and the company's reliance on dose interruption and reduction strategies to manage tolerability may not translate to real-world settings where primary care physicians lack specialized support, potentially undermining the touted adherence advantage over injectables that offer more predictable pharmacokinetics.
Structural manufacturing cost advantages as a small-molecule drug may be offset by intense pricing pressure in the obesity space, as Medicare coverage later this year and aggressive cash price cuts by Novo Nordisk and Eli Lilly could drive down reimbursement rates across the class, threatening Structure's profitability even if it achieves market share, particularly given its lack of scale, diversified revenue streams, or established commercial infrastructure compared to incumbent pharmaceutical giants.
The market may be overestimating the addressable population for oral obesity drugs, as primary care physician preference for pills does not guarantee uptake given persistent side effect burdens, lack of long-term safety data beyond 44 weeks, and potential formulary restrictions favoring established injectables with proven cardiovascular outcomes data, meaning Structure could capture far less than the anticipated share of the 100 million needing treatment, leaving its valuation dependent on successful Phase 3 outcomes that remain years away and subject to clinical trial failure risks inherent in mid-stage biotech programs.